CD4 and classic Hodgkin lymphoma: The proposed role played by CD4+ T-cells in the response to CPIs seen in cHL has been recently challenged by the analysis of selected patients enrolled in the NIVAHL trial, for which tissue samples obtained at diagnosis and after the first days of Nivo monotherapy were directly compared.